On February 5, 2026, the Food and Drug Administration (FDA) sent a letter to Novo Nordisk regarding its television advertisement for the Wegovy obesity pill.
The FDA stated that the ad includes "false or misleading" claims about the drug's benefits and abilities. This misbranding makes the distribution of the ad a violation of federal law, as indicated by the FDA in their communication.
Novo Nordisk has confirmed it received the FDA's letter and mentioned that the advertisement has been running since the pill's launch in January 2026. However, the company clarified that this ad is not associated with its Super Bowl advertisement.
Liz Skrbkova, Novo's head of U.S. media and stakeholder relations, stated, "We take all regulatory feedback seriously and are in the process of responding to the FDA to address their concerns regarding the advertisement's presentation." This shows the company's commitment to addressing the regulatory feedback promptly.
The Wegovy pill, which is the first GLP-1 pill for obesity to enter the market, has been taken by over 170,000 American patients.
Novo Nordisk is facing challenges as it attempts to reclaim market share from its main competitor, Eli Lilly, and from cheaper compounded versions of the drug. The company views the Wegovy pill as crucial for its success in the growing GLP-1 market.
The FDA's letter criticized the advertisement for suggesting that Wegovy provides superior benefits compared to other approved GLP-1 weight loss drugs.
The FDA pointed out that phrases used in the ad, such as "live lighter" and "a way forward," imply greater weight loss and additional benefits that are not supported by evidence. The FDA also noted that the ad misleadingly suggests emotional relief and other life improvements, which have not been demonstrated.
On the same day the FDA issued its letter, Novo Nordisk launched a lawsuit against the telehealth company Hims & Hers.
The lawsuit seeks to prevent Hims & Hers from mass marketing compounded versions of the Wegovy pill and injections. This legal action indicates the company's efforts to protect its market position and intellectual property in the rapidly evolving weight loss drug sector.
With the FDA's scrutiny and legal challenges, Novo Nordisk faces a critical moment in its efforts to secure its place in the obesity treatment market.
The Wegovy pill represents a significant advancement in weight loss medication, but the company must navigate regulatory concerns and competition effectively. As they respond to the FDA and pursue legal action against competitors, the outcome will be crucial for their future in the industry.
